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Abstract
The macrocycle family of molecules called cucurbit[n]urils are potential drug delivery vehicles as they are able to form host-
guest complexes with many different classes of drugs. This study aimed to examine the utility of cucurbit[6]uril (CB[6]) in
topical cream-based formulations for either localised treatment or for transdermal delivery. Cucurbit[6]uril was formulated
into both buffered cream aqueous- and oily cream-based dosage forms. The solid state interaction of CB[6] with other
excipients was studied by differential scanning calorimetry and the macrocycle’s transdermal permeability was determined
using rat skin. Significant solid state interactions were observed between CB[6] and the other dosage form excipients. At
concentrations up to 32% w/w the buffered aqueous cream maintained its normal consistency and could be effectively
applied to skin, but the oily cream was too stiff and is not suitable as a dosage form. Cucurbit[6]uril does not permeate
through skin; as such, the results imply that cucurbituril-based topical creams may potentially only have applications for
localised skin treatment and not for transdermal drug delivery.
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Introduction
A new family of macrocycles called cucurbit[n]urils (Fig. 1,
n=5–8, 10, 14) [1–5], have demonstrated potential as drug
delivery vehicles as they are able to form host-guest complexes
with many classes of drug [6–13]. The drugs are either partially or
wholly encapsulated within the macrocycle’s hydrophobic cavity
with encapsulation further stabilised through hydrogen bonding
and ion-dipole interactions between the drugs and the cucurbituril
portals [1,3,4,6].
Their formation into host-guest drug complexes has demon-
strated several important applications, including: increased drug
solubility [14–16], induced drug pKa shifts [17], biorecognition
[18–20], improved drug stability and reduced drug degradation
during manufacture, storage and within the human body [8,21–
24], taste masking of orally delivered drugs [8], modification of
drugs’ pharmacokinetics [25], and finally, investigation of photo-
controlled drug release [26]. As drug delivery vehicles, the most
commonly used sizes are CB[6], CB[7] and CB[8], as CB[5] is too
small to incorporate drugs and CB[10] is too large to adequately
bind drugs in its cavity [27–30]. As a new cucurbituril homologue,
no drug delivery studies of CB[14] have yet been undertaken [5].
To realise the drug delivery potential of cucurbiturils they must
be formulated into appropriate dosage forms for human use, but to
date there has been little investigation into cucurbituril formula-
tion. Previously we have examined solid oral dosage forms of
cucurbituril [7]. Using microcrystalline CB[6], tablets containing
up to 50% w/w cucurbituril could be manufactured with suitable
tablet hardness, surface smoothness and tablet disintegration times
in both simulated gastric and intestinal fluid [7].
Cucurbiturils are known to form host-guest complexes with a
range of drugs that have applications in dermal and transdermal
delivery. For example, cucurbiturils are able to bind nicotine
which has application as a slow release formulation [31]. They are
also able to bind local anaesthetics such as procainamide,
tetracaine, procaine and prilocaine [32], and can also bind
fungicides such as carboxin [33], fuberidazole [34] and thiaben-
dazole [16]. Therefore, as part of a wider cucurbituril dosage
formulation project in our group it was of interest to develop
topical cream-based formulations of cucurbituril for dermal and
transdermal drug delivery.
In this work the utility of CB[6] as an effective excipient in
topical formulations was studied using two common base creams
from the Australian Pharmaceutical Formulary and Handbook
22nd edition (APF22): buffered cream aqueous (BCA) and oily
cream [35]. Dosage forms of both creams were manufactured
containing CB[6] and the macrocycle’s solid state interactions with
the other dosage form excipients was examined. The permeability
of CB[6] was examined using rat skin and monitored by
fluorescence spectroscopy.
Materials and Methods
Materials
Glycoluril, hydrochloric acid (37%), 1,6-dibromohexane, deu-
terium oxide (99.9%), deuterium chloride (35%), isoquinoline and
chlorocresol (4-chloro-3-methyphenol) were purchased from Sig-
ma-Aldrich. Paraformaldehyde was purchased from AlfaAesar.
Phenoxyethanol, zinc oxide BP, lanolin anhydrous and citric acid
monohydrate were purchased from the Sydney Essential Oil
Company. Cetostearyl alcohol was purchased from Bronson and
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Jacobs. White soft paraffin was supplied by The University of
Sydney Dispensing Laboratory. Sodium phosphate BP was
purchased from the Government Store Department. 1,4-dioxane,
calcium hydroxide solution and sulfuric acid were purchased from
Merck. Arachis oil was purchased from Proteco and oleic acid
from Professional Compounding Chemists of Australia. All water
was obtained from an SG ultra clear water system. Phosphate
buffered saline (PBS) solutions were made using pure water and
PBS tablets from Sigma Life Sciences. All other chemicals
including: methanol, ethanol and diethyl ether, were of analytical
reagent grade.
CB[6] Synthesis and Processing
Cucurbit[6]uril was synthesised and purified using an adapta-
tion of the method of Walker et al. [7]. Glycouril (20 g) was
dissolved in sulfuric acid (98%, 110 mL) at 70uC. Paraformalde-
hyde (8.8 g) was then added and the solution stirred at 70uC
overnight. The solution was allowed to cool to room temperature
before CB[6] was precipitated by the addition of ,1700 mL
methanol. The solution was left to settle for 1 day before the
methanol/acid supernatant was decanted. This purification
process was repeated a second time. The solution was then heated
to ,50uC for several hours to aid evaporation of any remaining
methanol. Next, the precipitate was dissolved in a minimum
amount (,100–200 mL) of hot concentrated HCl. The solution
was then cooled to 220uC to crystallise pure CB[6]. The solution
was decanted and the solution placed back in the freezer to allow
for further crystallisation. The remaining crystals were collected
via vacuum filtration using grade 1 filter paper, washed with water,
air-dried for , 1 h and oven-dried at , 100uC for several hours.
Synthesis of fluorescence guest for tracking CB[6]
The fluorescence marker, 2,29-(hexane-1,6diyl)diisoquinoli-
nium, was synthesised using an adaptation of the method Fan
et al [36]; however, production of the fluorescence marker
following this method does not result in a pure product. After
collection of the product by filtration at the end of the synthesis
and purification method in the paper, the fluorescence marker was
then additionally redissolved in a minimum volume of ethanol and
left to recrystallise through the slow addition of gaseous diethyl
ether. The resultant crystals were collected by vacuum filtration on
nylon filter paper (0.2 mm), washed with diethyl ether and air-
dried for several hours.
Fluorescence calibration graph
A series of dilutions from 1 to 10 mM of the free fluorescent
marker and the fluorescent marker in CB[6] in water were
prepared to obtain calibration graphs. Fluorescence spectra were
measured on a Shimadzu RF-5301 PC spectrofluorometer with
excitation and emission wavelengths of 338 nm and 377 nm
respectively, through a quartz cuvette with a path length of 1 cm.
Emulsifying ointment preparation
Emulsifying ointment was prepared as described in the APF22
[35]. Emulsifying wax (300 g), white soft paraffin (500 g) and
liquid paraffin (200 g) were melted together in a large plastic
beaker in a microwave in 1 min bursts. The ingredients were
stirred with a spatula until mixed and then cooled to room
temperature.
Preparation of cream formulations - Buffered cream
aqueous
Buffered cream aqueous, as described in the APF22, was
prepared by mixing a lipophilic and an aqueous phase together at
,70uC. The aqueous phase was made by dissolving sodium
phosphate (2.5 g), citric acid monohydrate (0.5 g) and chlorocresol
(0.1 g) in water (,60 mL) in a glass beaker on a hotplate (.80uC)
with stirring. The beaker was covered with a watch glass to reduce
solvent evaporation. The lipophilic phase consisted solely of
emulsifying ointment (30 g), which was melted using a microwave
oven and in a plastic beaker with 10 s bursts of energy. The
aqueous phase was then added to the melted emulsifying ointment
and immediately mixed with a spatula until it cooled and formed a
semi-solid. As the cream formed, the weight was adjusted with
water to a final total mass of 100 g. In later experiments, as an
alternate preservative, chlorocresol was replaced with phenox-
yethanol (1 mL), which was added after mixing both phases.
Preparation of cream formulations - Oily cream
Zinc cream oily and oily cream samples were produced
according to the APF22. Preparation of the zinc cream involved
mixing a lipophilic and an aqueous phase together in a mortar and
pestle. The mortar was first heated with hot water and then dried
thoroughly. Zinc oxide (6.4 g) was added to lanolin anhydrous
(3.5 g) in the mortar. The zinc oxide was incorporated carefully
into the lanolin anhydrous to ensure even distribution. Arachis oil
(4.3 mL) was added slowly using a pipette to dissolve the lanolin
anhydrous. Oleic acid (0.1 mL) was then added using a pipette.
The lipophilic phase was mixed in the mortar and pestle until all
the lanolin dissolved. The aqueous phase, consisting of a calcium
hydroxide solution (1% w/v, 6.1 mL), was added to the mortar in
several portions and mixed thoroughly after each addition until
the solution was completely incorporated. For preparations of
cucurbituril-based oily cream formulations, the zinc oxide in the
formulation was replaced with CB[6].
Incorporation and formulation of CB[6] into the creams
Cucurbit[6]uril was formulated into the creams by two
methods: either by dissolution in the aqueous phase or incorpo-
ration as a fine powder. To aid dissolution, the CB[6] crystals were
first ground to a fine powder in a mortar and pestle. To determine
the amount of CB[6] that could be dissolved in the aqueous phase
of the BCA formulation, CB[6] (added in 50 mg increments until
solution saturation) was added to a solution containing sodium
phosphate (2.5 g) and citric acid monohydrate (0.5 g) in water
(,60 mL) at .80uC with stirring. Once dissolved, the solution
was allowed to cool to room temperature. The solubility was
Figure 1. The chemical structure of cucurbit[n]urils (n=5, 6, 7,
8, 10 or 14 subunits) and a molecular model of the
cucurbit[6]uril homologue based on its single crystal X-ray
structure.
doi:10.1371/journal.pone.0085361.g001
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determined by the maximum amount of CB[6] that dissolved in
the solution without recrystallisation once the solution had cooled
to room temperature.
An alternate method of formulating CB[6] into the creams
involved incorporating CB[6] as a fine powder. Cucurbit[6]uril
was incorporated into the BCA by the method of doubling to the
final cream. In the oily cream, ground CB[6] powder was
incorporated into the lanolin anhydrous in the mortar in the initial
stages of the cream preparation instead of the excipient normally
used, zinc oxide. The arachis oil and oleic acid were then added to
the mortar. The lipophilic phase was mixed in the mortar and
pestle until all the lanolin anhydrous dissolved. The aqueous
phase, which consisted of calcium hydroxide solution, was then
added to the mortar in several portions and mixed thoroughly
after each addition until the solution was completely incorporated.
Solid state interactions
Interactions between CB[6] and the other dosage form
excipients that are solids at room temperature were studied using
differential scanning calorimetry (DSC). A standard Cell 2920
modulated DSC supplied with a liquid nitrogen system at a flow
rate of 60 mL/min was used. Individual samples were weighed
accurately in Tzero aluminium crucibles with a similar empty
crucible used as a reference. Each sample was heated at a rate of
5uC/min from 0 to ,10uC above the excipient’s known melting
point. The data were collected and analysed using a Universal
V4.2E TA instrument.
Thermogravimetric Analysis
Thermogravimetric analysis (TGA) was conducted using a Hi-
Res TGA 2950 instrument. Citric acid monohydrate and CB[6]
samples were weighed on tared platinum pans and heated at a rate
of 2uC/min to 120uC and 350uC, respectively. The data were
collected and analysed using a Universal V4.2E TA instrument.
Cucurbit[6]uril skin permeability
Male and female Australian albino white (AAW) rats were
obtained previously euthanised with pCO2 from the Laboratory
Animal Services at The University of Sydney after their use in
behavioural projects had been finalised (Animal Ethics Committee
approval number L29/5-12/3/5765). The abdominal fur was
clipped and carefully shaved (to better represent human skin) using
a razor and scalpel before the abdominal skin was then surgically
excised. The skin samples were stored in phosphate buffered saline
(PBS) solution at 4uC until use. The abdominal area of the excised
skin on each rat was measured with a ruler and the average area
was calculated. Prior to undertaking skin permeability tests, each
piece of skin was restretched to the average length and width it
would have been on the animal using a cork board and pins. Any
remaining fur on the skin was removed using a scalpel. Samples of
each cream containing either free fluorescent marker or CB[6]
encapsulated fluorescent marker (40 mg of cream in total per
sample) was applied to skin samples on a PermaGear 25 mm
Franz cells with a receiver volume of 20 mL. The reservoir was
filled with PBS and kept at 37uC by stirring (500 rpm) and
immersion in a water bath. Solution samples were taken from the
reservoir 1 h after application of the creams to the skin.
Results and Discussion
The purpose of this work was to assess the utility of cucurbiturils
as an effective excipient in topical cream dosage forms for localised
and transdermal drug delivery. Cucurbit[6]uril was selected as a
representative macrocycle from the cucurbituril family as it is the
cheapest and easiest to use for research purposes [7].
Cucurbit[6]uril processing
Our previous method of processing CB[6] involved several
repetitive steps which are time consuming and result in a low yield
of CB[6] crystals [7]. This old method involves collecting the
CB[6] precipitate by vacuum filtration and then washing it with
copious amounts of water. It would then need to be collected and
dried under vacuum, and redissolved in a minimum volume of
concentrated HCl. The solution would then be left for a period of
days to weeks to allow for crystallisation of pure CB[6] crystals.
Finally, using this old method, the CB[6] crystals are washed with
a HCl/water solution, rinsed with pure water, then collected via
vacuum filtration and oven dried at 110uC for several hours.
A new and more efficient method of processing CB[6] was
therefore developed to obtain a faster and higher yield of pure
CB[6] crystals. This method involved precipitating CB[6] from the
acid solution directly after synthesis by the addition of copious
amounts of methanol. The solution is left to form a precipitate
before the acid/methanol supernatant is decanted. This process is
repeated a second time before the precipitate and any small
amount of remaining solution are then heated to aid evaporation
of any remaining methanol until a sludge-like residue forms. The
precipitate is then dissolved in a minimum amount of hot
concentrated HCl, the solution cooled to 220uC overnight and
the crystals collected via vacuum filtration. This purification
method results in a higher yield of pure CB[6] crystals and is also
less time consuming since it consists of fewer preparation steps
compared with the old method.
Cucurbit[6]uril-excipient solid state interactions
As a novel excipient in human topical dosage forms, CB[6] may
interact positively or negatively with the other excipients in the
creams, including chlorocresol, cetostearyl alcohol, white soft
paraffin, etc. Differential scanning calorimetry (DSC) can be
employed to determine whether CB[6] physically interacts with
any of these excipients [7,37]. Each excipient was first analysed by
DSC to attain baseline values. Then 50:50 w/w mixtures of CB[6]
with each excipient were prepared by grinding them together in a
mortar and pestle and analysed by DSC.
Significant solid state interactions were observed between CB[6]
and most excipients. Consistent with the literature, the DSC of
chlorocresol shows a peak at 69uC with an enthalpy of fusion of
146.7 J/g (Fig. 2) [38]. The addition of CB[6] resulted in a
reduction in the melting point to 64uC and a decrease in the peak
size to 62.76 J/g. Cetostearyl alcohol has a melting range from 48
– 56uC [38]. In this study two peaks are observed at 43 and 53uC,
the latter with an enthalpy of fusion of 115.1 J/g (Fig. 3). The
DSC of cetostearyl alcohol with the addition of CB[6] displayed
significant changes including a new peak at 27uC, a drop to a
lower temperature of the peak previously at 43uC, a slight increase
in the melting point of the major peak to 55uC and a significant
drop in its enthalpy by 54% to 62.03 J/g.
Two DSC peaks were observed with citric acid monohydrate;
one distinct peak at 54uC and another broad peak between 30 and
95uC (Fig. 4). While the addition of CB[6] causes the first peak to
shift up to a higher temperature (64uC), the second peak remains
relatively unchanged. To identify which peak accounted for the
release of a water molecule and which the melting of the citric
acid, samples of citric acid monohydrate and citric acid
monohydrate ground in a 50:50 w/w ratio with CB[6] were
analysed by TGA. The TGA results for citric acid monohydrate
demonstrate a 5% weight loss at 30–50uC. For the citric acid-
Topical Creams of Cucurbituril
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CB[6] mixture a 7% weight loss between 30–60uC is observed.
From these results we can assume that the first peak (54/64uC)
most likely coincides with the loss of water from both the citric acid
and the waters of hydration of the cucurbituril and explains its
movement to a higher temperature. The second broad peak was
therefore assigned as the melting of the citric acid which has
previously been shown to occur around 75uC [38]. Its drop from
88uC to 72uC indicates a significant interaction with the CB[6].
The DSC of white soft paraffin shows two peaks between 10 and
45uC, and 45 and 60uC (Fig. 5). When ground with CB[6] the two
peaks combine into one distinct peak at 43uC. The enthalpy of
fusion could not be accurately determined as it was difficult to
distinguish the start and end point of the peaks. The DSC of
lanolin anhydrous displays three peaks between 38 and 52uC
(Fig. 6). The addition of CB[6] results in a positive peak at 42uC
which may suggest a glass transition occurs at this point. Grinding
CB[6] with lanolin anhydrous also shifts the three peaks slightly up
to 41–55uC with much less distinction between the peaks.
Overall, the results demonstrate that the CB[6] has measurable
solid-state interactions with many of the excipients in the BCA and
oily cream formulations; however, it is impossible to determine
whether these interactions would impact the performance of the
CB[6] and subsequent drug host-guest complexes.
Figure 2. The differential scanning calorimetry curves of chlorocresol (solid line) and chlorocresol ground with CB[6] in a 50:50 w/w
ratio (broken line).
doi:10.1371/journal.pone.0085361.g002
Figure 3. The differential scanning calorimetry curves of cetostearyl alcohol (solid line) and cetostearyl alcohol ground with CB[6]
in a 50:50 w/w ratio (broken line).
doi:10.1371/journal.pone.0085361.g003
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Formulation of CB[6] into topical cream-based dosage
forms
Prior to examining CB[6] skin permeability, it was first
necessary to assess the ability of CB[6] to be formulated into
different topical dosage forms. Additionally, the maximum amount
of CB[6] that could be formulated into each dosage form and still
produce an effective product was investigated. Two topical creams
were chosen as base formulations to investigate these aims.
Aqueous-based and oily-based creams were selected to assess
which formulation would better incorporate and deliver CB[6]
into, and possibly through, skin. These creams included buffered
cream aqueous (BCA) and an adaptation of the zinc cream oily
formulation, both described in the APF22.
Preparation of cream formulations
Cucurbit[6]uril was formulated into the creams by two
methods: either by dissolving in the aqueous phase of each cream
or incorporation into the prepared cream as a powder. Initially,
attempts to dissolve CB[6] in the aqueous phase of the BCA were
unsuccessful as the presence of chlorocresol with CB[6] resulted in
the formation of an insoluble precipitate. Because of this
chlorocresol is an incompatible excipient with CB[6] in liquid
and semi-solid dosage forms. Instead, phenoxyethanol was selected
as an alternate, which is a common preservative utilised in many
topical dosage forms [39]. Subsequent dissolution experiments of
CB[6] in the aqueous phase of BCA using phenoxyethanol did not
result in any observable recrystallisation of CB[6] out of the
solution by eye or under an optical microscope.
Once formulated in BCA it was important to determine if
CB[6] retained its solubility. Figure 7 shows optical microscope
images of CB[6] and formulations containing CB[6]. When the
Figure 4. The differential scanning calorimetry curves of citric acid monohydrate (solid line) and citric acid monohydrate ground
with CB[6] in a 50:50 w/w ratio (broken line).
doi:10.1371/journal.pone.0085361.g004
Figure 5. The differential scanning calorimetry curves of white soft paraffin (broken line) and white soft paraffin ground with CB[6]
in a 50:50 w/w ratio (solid line).
doi:10.1371/journal.pone.0085361.g005
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CB[6] concentration is 2–4% w/w dissolved in the aqueous phase
of the BCA and mixed with 5 g of emulsifying ointment, the
resulting formulation does not display any CB[6] crystals. This
may suggest that CB[6] remains in solution even when the CB[6]
content in the aqueous phase is relatively high compared to the
lipophilic phase (since the lipophilic phase should be 30 g
according to the APF22). The absence of observable CB[6]
crystals in Figures 7C and 7D may however suggest that either an
insufficient amount of CB[6] was added to the cream to be
detected visually or that the crystals remain in solution.
Attempts to dissolve CB[6] in the aqueous phase of the oily
cream, which consisted of calcium hydroxide solution (30.5 mL)
on a hotplate at .80uC with stirring were unsuccessful even after
several hours. As a result, CB[6] was only able to be incorporated
into the oily cream as a powder.
Observing the samples under an optical microscope also
allowed for the detection of differences between formulating
CB[6] into the BCA via dissolution in the aqueous phase and
incorporation as a powder. Figures 7E and 7F illustrate the
incorporation of CB[6] powder in the BCA and the oily cream at a
concentration of 32% w/w, respectively. Figure 7E shows the
presence of observable CB[6] crystals in the BCA formulation
which indicates that CB[6] remains in the solid state in the cream
and does not dissolve in the final product. In contrast, Figure 7F
does not display any observable CB[6] crystals when incorporated
as a solid into the oily cream even at the high concentration of
32% w/w. This indicates that CB[6] dissolves in the oily cream;
despite not being soluble in the aqueous phase of the cream before
production.
Maximum CB[6] content formulated into cream
The maximum amount of CB[6] that can be dissolved in the
aqueous phase of BCA and incorporated as a powder into the
creams was investigated. This was done by adding CB[6] in 50 mg
increments into the aqueous phase of BCA until solution
saturation. It was found that 0.5% w/w (5.3 mM) CB[6] is the
maximum amount that can be dissolved in the aqueous phase of
BCA. This result is consistent with the solubility of CB[6] in other
highly ionic solutions such as simulated gastric fluid (1–4 mM) and
simulated intestinal fluid (5–7 mM) [6]. By comparison, in pure
Figure 6. The differential scanning calorimetry curves of lanolin anhydrous (solid line) and lanolin anhydrous ground with CB[6] in
a 50:50 w/w ratio (broken line).
doi:10.1371/journal.pone.0085361.g006
Figure 7. Optical microscope images of (A) CB[6] ground to a
fine powder, (B) buffered cream aqueous with phenoxyethanol
as the preservative, with no added CB[6], (C) 5% w/w CB[6]
dissolved in the aqueous phase of BCA with phenoxyethanol,
(D) 2–4% w/w CB[6] dissolved in the aqueous phase of BCA and
mixed with 5 g of emulsifying ointment only, (E) 32% w/w
CB[6] powder incorporated in buffered cream aqueous show-
ing solid CB[6] particles in the formulation, and (F) 32% w/w
CB[6] powder incorporated in oily cream. The latter panel (F)
shows that the CB[6] dissolves in the oily cream completely.
doi:10.1371/journal.pone.0085361.g007
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water CB[6] has a solubility of less than 0.02 mM [1]. All
concentrations higher than 0.5% w/w resulted in observable
amounts of recrystallised CB[6] upon cooling of the solutions. At
0.5% w/w no recrystallisation of CB[6] was observed even after
the cream was completely formulated as indicated by the absence
of CB[6] crystals in Figure 7C.
The maximum concentration of CB[6] that could be incorpo-
rated as a powder was measured by the amount of powder that
can be absorbed into the skin, such that no observable powder or
white residue remains on the surface of the skin. The zinc cream
oily however contains 32% w/w zinc oxide powder and it was
necessary to keep this fraction constant as altering the proportion
of powder in the formulation may modify the properties of the
cream. Whilst concentrations of CB[6] in the BCA of between 0.5
and 32% w/w has no obvious effects on the viscosity of the cream,
the addition of CB[6] in oily cream at a concentration of 32% w/
w resulted in a highly viscous and stiff product which was difficult
to apply. As such, the oily cream was evaluated as an unsuitable
formulation for the delivery of CB[6] and potentially other sized
cucurbiturils.
Skin permeability
Although human skin samples are ideal for permeability
investigations they are not easily accessible. Nonetheless, studies
have reported porcine [40–42] and rat skin [43–45] as good
models for human skin since they exhibit similar anatomical and
morphological characteristics. In this study skin from Australian
albino white (AAW) rats was used as a suitable model.
Before skin permeation studies were conducted the ability of
CB[6] to deposit into the skin was assessed by determining if any
white residue remained on the skin surface after sample
application. Each sample was applied using a spatula over a
4 cm2 area using BCA (5 mg) and BCA with 32% w/w CB[6]
(5 mg). Upon examination of all samples, no observable powder or
white residue remained on the surface of the skin, even after
several hours. These results may suggest that CB[6] is able to
penetrate into skin, although it cannot be discounted that the
CB[6] does not penetrate the skin and human eyesight is too poor
to detect CB[6] crystals on the skin surface visually.
The transport of CB[6] through skin was then examined with
fluorescently marked CB[6] using Franz cells with a PBS reservoir.
The free fluorescent marker 2,29-(hexane-1,6diyl)diisoquinolinium
in a 20% w/w BCA formulation is able to readily permeate
through the skin. After 1 h the fluorescent intensity of the PBS
solution is 28 which gave a fluorescent marker concentration of
2 mM in the reservoir (Fig. 8). When the fluorescent marker is
encapsulated within CB[6] the hydrophobic environment increas-
es the fluorescence of the marker by 25% and shifts the maximum
to a lower wavelength [7]. When encapsulated by CB[6] the
amount of fluorescent marker that is able to permeate through the
skin is significantly lower. Cucurbit[6]uril encapsulation results in
a fluorescence intensity drop to between 2–3 which is a decrease of
92%. When fluorescence enhancement by CB[6] of the marker is
taken into account that the actual amount of CB[6]-fluorescent
marker that has permeated through the skin is just 6% compared
with the free fluorescent marker. This result suggests that CB[6]
does not permeate easily through skin in the BCA formulation and
therefore may have more application in localised skin treatment
than it does for transdermal drug delivery applications. Potential
applications could include the treatment of wounds or skin-based
diseases such as psoriasis and eczema and it could be used to
increase the residence times of the active pharmaceutical
ingredients of sunscreens. It is important to note, however, that
CB[6] is just one homologue from the cucurbituril family and the
other sized cucurbiturils may display different skin permeability.
Likewise, different topical dosage forms may also display different
skin permeability for CB[6] and other homologues.
Conclusions
The macrocycle CB[6] was formulated into buffered cream
aqueous and an oily cream. Cucurbit[6]uril was shown to have
solid state interactions with the excipients in both dosage
formulations and when added to the oily cream produced a
product too viscous and stiff to perform as an appropriate
medicinal product. Cucurbit[6]uril in the BCA formulation does
not permeate easily through skin, which means its drug delivery
applications may be limited to localised treatments only. Further
research using different sized cucurbiturils and with different
topical dosage forms is warranted to determine if cucurbiturils can
be used in transdermal applications.
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